Percutaneous coronary mediations are being utilized with expanding recurrence these days for the treatment of patients with coronary illness. Intense thrombotic difficulties stay one of the real limits of these techniques for which unfractionated heparin has been the standard establishment anticoagulant. It has, notwithstanding, numerous limits and impediments that required innovative work of option anticoagulant treatments. The immediate thrombin inhibitor bivalirudin has been endorsed as a substitute for heparin in patients experiencing angioplasty for temperamental angina in light of information in higher-hazard patients where bivalirudin brought about lower rates of ischaemic and draining inconveniences contrasted with heparin. Bivalirudin is an individual from the immediate thrombin inhibitor gathering of anticoagulants. It has been assessed as a distinct option for unfractionated and low-atomic weight heparins in the settings of percutaneous coronary mediation (PCI) and intense coronary disorder (ACS). Aftereffects of clinical trials to date propose bivalirudin is a feasible distinct option for the utilization of a heparin consolidated with a glycoprotein (GP) IIb/IIIa inhibitor in these settings. Thrombin has a focal part in coagulation and platelet initiation in ACS and amid PCI. Its direct restraint is an appealing focus for treatment in these settings. Bivalirudin is a 20 amino corrosive polypeptide hirudin simple. It shows bivalent and reversible tying to the thrombin particle, restraining its activity. Direct hindrance of thrombin with bivalirudin has hypothetical pharmacokinetic and pharmacodynamic favorable circumstances over the backhanded anticoagulants.